8 completed. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 1 | Completed 1 |
Follow Hyperaldosteronism: new trials by email Literature Review of Hyperaldosteronism trials Research Report on Hyperaldosteronism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CIN-107 in Adults With Primary Aldosteronism CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing - Primary Aldosteronism, Hyperaldosteronism | Phase 2 | Completed | AstraZeneca | 15 | 2021-03-08 | 2026-03-03 |
| Calcium Channel Blockade in Primary Aldosteronism Amlodipine - Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Phase 2 | Completed | Brigham and Women's Hospital | 15 | 2020-09-01 | 2025-04-15 |
| 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre - Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism | Phase 2 / Phase 3 | Completed | Changi General Hospital | 97 | 2019-12-30 | 2026-10-26 |
| DP13 - A Phase II Study in Patients With Primary Aldosteronism dexfadrostat phosphate - Primary Aldosteronism | Phase 2 | Completed | Damian Pharma AG | 35 | 2019-11-21 | 2024-11-22 |
| Open-label Study on Treatment of Primary Aldosteronism With Everolimus Everolimus 0.75 mg - Primary Aldosteronism | Phase 2 | Completed | University Hospital, Basel, Switzerland | 12 | 2017-05-22 | 2019-01-09 |
| Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy Abiraterone Acetate, Prednisone 5 mg twice daily, Prednisone 5 mg once daily - Prostate Cancer | Phase 2 | Completed | Janssen Pharmaceutica N.V., Belgium | 164 | 2013-07-16 | 2019-07-05 |
| The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension Eplerenone, Amlodipine, Microneurography - Hypertension | Phase 2 | Completed | University of Texas Southwestern Medical Center | 14 | 2013-07-01 | 2022-03-18 |
| Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism LCI699 - Primary Hyperaldosteronism | Phase 2 | Completed | Novartis | 12 | 2008-06-01 | 2009-08-26 |
Hypertension (2) · Adrenal Gland Neoplasms (1) · Hypokalemia (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
Adrenal Gland Diseases (8) · Adrenocortical Hyperfunction (8) · Endocrine System Diseases (8) · Cardiovascular Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Vascular Diseases (2) · Endocrine Gland Neoplasms (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Neoplastic Processes (1) · Nutritional and Metabolic Diseases (1)
Amlodipine (2) · Abiraterone Acetate (1) · Dexamethasone (1) · Eplerenone (1) · Everolimus (1) · Osilodrostat (1) · Prednisone (1)
AstraZeneca (1) · Brigham and Women's Hospital (1) · Changi General Hospital (1) · Damian Pharma AG (1) · Janssen Pharmaceutica N.V., Belgium (1) · Novartis (1) · University Hospital, Basel, Switzerland (1) · University of Texas Southwestern Medical Center (1)
United States (3) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Singapore (1) · Switzerland (1) · United Kingdom (1)
Anand Vaidya, MD (1) · Marc Y Donath, Prof. (1) · Paolo Mulatero, Prof (1) · Wanpen Vongpatanasin, MD (1)
PMID 20837883, PMID 24107737, PMID 31246234, PMID 32923850, PMID 33794293, PMID 37490693